Clin2
NCT06585514Possibly a fitRecruiting

CAR T-cell therapy for hard-to-treat lupus

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)

Treatments studied

Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.

This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
18 people
Ages
3 years to 65 years
Study type
Interventional

Who can take part

  • You are between 3 and 65 years old.
  • You have been diagnosed with systemic lupus erythematosus (SLE) by a doctor.
  • Your lupus is not controlled with usual treatments, or you have lupus-related kidney disease that is not improving.
  • You are willing to stop taking your lupus medications for at least one week before the treatment.
  • You do not have serious heart, lung, or other major organ problems.
  • You are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06900764Not yet recruiting
CAR-T cell therapy for lupus

This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.

Wuhan, Hubei
NCT07444307Recruiting· Phase 1
CAR-T cell therapy for hard-to-treat lupus

This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.

Hefei, Anhui
NCT06946485Recruiting· Early Phase 1
CAR-T cell therapy for hard-to-treat lupus

This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.

Nanjing, Jiangsu
NCT06350110Recruiting· Phase 1/Phase 2
CAR T cells for lupus

This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.

Beijing, Beijing Municipality
NCT06688799Recruiting· Phase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases

This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.

Beijing, Beijing Municipality
NCT07432334Recruiting· Phase 1
CAR T-cell therapy for hard-to-treat lupus

This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.

Hanoi

Hear when a new Systemic Lupus Erythematosus (SLE) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.